Siplizumab - ITBMed Biopharmaceuticals

Drug Profile

Siplizumab - ITBMed Biopharmaceuticals

Alternative Names: MEDI-507

Latest Information Update: 26 Jun 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Catholic University of Louvain
  • Developer BioTransplant (CEASED); MedImmune
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action CD2 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Graft-versus-host disease; Psoriasis; Psoriatic arthritis; Renal transplant rejection; Rheumatoid arthritis; T cell lymphoma

Most Recent Events

  • 26 Jun 2007 Discontinued - Phase-I for T-cell lymphoma in USA (IV)
  • 19 Jun 2007 MedImmune has been acquired by AstraZeneca
  • 30 Jun 2006 Siplizumab has been recommended for orphan drug status for T and NK cell neoplasms in the European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top